Post-traumatic Stress Disorder Therapeutics Market by Product and Geography - Forecast and Analysis 2020-2024

The post-traumatic stress disorder therapeutics market size has the potential to grow by USD 909.86 million during 2020-2024, and the market’s growth momentum will accelerate during the forecast period.

This report provides a detailed analysis of the market by product (antidepressants, anxiolytics, and other PTSD therapeutics) and geography (APAC, Europe, MEA, North America, and South America). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Mylan NV, Neurocrine Biosciences Inc., Novartis International AG, and Pfizer Inc.

Market Overview

Market Competitive Analysis

The market is fragmented with the presence of numerous international and regional vendors. However, the market has been recording an increase in mergers and acquisitions, which is helping vendors in expanding their presence in different regions and product portfolios for achieving economies of scale. H. Lundbeck AS, Mylan NV, Neurocrine Biosciences Inc., Novartis International AG, and Pfizer Inc. are some of the major market participants. Although the rising prevalence of post-traumatic stress disorder (PTSD) will offer immense growth opportunities, the lack of quality research in PTSD treatment will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

To help clients improve their market positions, this post-traumatic stress disorder therapeutics market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this post-traumatic stress disorder therapeutics market analysis report also provides information on the upcoming post-traumatic stress disorder therapeutics trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.

This report provides information on the production, sustainability, and prospects of several leading companies, including:

• AstraZeneca Plc
• Azevan Pharmaceuticals Inc.
• Bionomics Ltd.
• Eli Lilly and Co.
• GlaxoSmithKline Plc
• H. Lundbeck AS
• Mylan NV
• Neurocrine Biosciences, Inc.
• Novartis International AG
• Pfizer Inc.

Post-traumatic Stress Disorder Therapeutics Market: Segmentation by Region

North America was the largest post-traumatic stress disorder therapeutics market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. The rising spending on the treatment of anxiety disorders, the growing initiatives to increase awareness about PTSD, and the increasing number of trauma-related cases such as assaultive violence will significantly influence post-traumatic stress disorder therapeutics market growth in this region.

Over 38% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for post-traumatic stress disorder therapeutics in North America. Market growth in this region will be slower than the growth of the market in APAC.

Post-traumatic Stress Disorder Therapeutics Market: Segmentation by Product

The high prescriptions of SSRIs, as these drugs are only approved for the treatment of PTSD, and the increasing awareness about the clinical benefits of antidepressants are contributing to the post-traumatic stress disorder therapeutics market share growth. Branded and generic ZOLOFT (sertraline) and PAXIL (paroxetine) are the first-line medications for adults with PTSD.

Market growth by the antidepressants segment will be faster than the growth of the market by the other segments. This report provides an accurate prediction of the contribution of all the segments to the growth of the post-traumatic stress disorder therapeutics market size.

Post-traumatic Stress Disorder Therapeutics Market: Key Drivers and Trends

The rising prevalence of PTSD has been identified as one of the key post-traumatic stress disorder therapeutics market. Approximately 6-8 out of 10 people that are victims of severe traumatic events develop PTSD. Events such as assaultive violence, childhood maltreatment, witnessing injury/trauma to others, serious accidents and illnesses, unexpected death of family member or friend, and natural disasters can cause PTSD. Therefore, the sales of many pharmacologic agents such as MDMA, ketamine, and glucocorticoids are gaining prominence and R&D focus. These agents are also being treated as novel pharmacotherapies for PTSD and several clinical trials are being conducted to check the effectiveness of these agents to treat PTSD in various phases. It is observed that MDMA enhances the therapeutic process for PTSD as it reduces fear and defensiveness, increases empathy and compassion, and enhances communication and introspection.

• Several public and private organizations are taking initiatives to raise awareness about PTSD and improve access to its treatment.
• To bring greater awareness about PTSD, the US Senate has designated June 27th as the national PTSD awareness day. In addition, the National Center for PTSD (NCPTSD) has designated June as PTSD awareness month.
• In Australia, Picking Up The Peaces is a non-profit organization that aims to reduce the stigma associated with PTSD. It supports people with PTSD, helps them to recognize the symptoms of PTSD, and encourages them to seek treatment.
• The global post-traumatic stress disorder therapeutics market is expected to grow at a CAGR of over 9% during 2020-2024. 

Post-traumatic Stress Disorder Therapeutics Market: Key Highlights of the Report for the Forecast Period 2020-2024

• CAGR of the market during the forecast period 2020-2024
• Detailed information on factors that will drive post-traumatic stress disorder therapeutics market growth during the next five years
• Precise estimation of the post-traumatic stress disorder therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the post-traumatic stress disorder therapeutics market industry across APAC, Europe, MEA, North America, and South America
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of post-traumatic stress disorder therapeutics market vendors